Results 231 to 240 of about 3,028,209 (373)

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Expert consensus on the off-label use of drugs for pediatric rare diseases in China (2025 edition). [PDF]

Transl Pediatr
Mo X, Deng H, Yang J, Li J, Ouyang S, Chen F, Cui Y, Gao X, Jiang H, Li X, Liu L, Liu J, Qiu L, Rong X, Wen Z, Wang J, Zeng P, Zhang W, Zhao X, Zhou J, Chen J, Chen P, Chen W, Chen Z, Fang R, Fan X, Jia Y, Li Z, Li X, Li X, Lin Y, Liu M, Mai H, Miao J, Wang X, Wang Y, Wang J, Wei L, Wu J, Yu S, Zeng L, Zhang B, Zhang H, Zheng Z, Chen X, Xia S, Zhou W, Sun J, Li Y, Rare Disease Expert Committee of Guangdong Pharmaceutical Association.   +49 more
europepmc   +1 more source

Safety and Efficacy of Using Advanced Hybrid Closed Loop Off-Label in an Infant Diagnosed with Permanent Neonatal Diabetes Mellitus: A Case Report and a Look to the Future [PDF]

Federico Pezzotta, Nicola Sarale, Giordano Spacco, Giacomo Tantari, Enrica Bertelli, Giulia Bracciolini, Andrea Secco, Giuseppe d’Annunzio, Mohamad Maghnie, Nicola Minuto, Marta Bassi   +10 more
openalex   +1 more source

Tackling Off-Label Use of Anticancer Drugs [PDF]

, 2012
Francesco Perrone, Filippo de Braud, Roberto Labianca, Carlo Tomino, Fausto Roila   +4 more
openalex   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Off-Label Use of the Multifunctional Occluder for Transcatheter Patent Ductus Arteriosus Closure: An International Experience. [PDF]

J Am Heart Assoc
Lwin N, Ovaert C, Malekzadeh-Milani S, Padovani P, Krasemann T, Georgiev S, Werner O, Houeijeh A, Douchin S, Kramer P, Scarduelli L, Bianco L, Grunenwald C, Hascoët S, Jalal Z, Benbrik N, Lefort B, Navarro Castellanos I, Schubert S, Fraisse A, Baruteau AE.   +20 more
europepmc   +1 more source

Safety of the Off-Label Use of Antitumor Drugs in Real Clinical Practice: Experience of Oncologists of the Russian Federation

Е. В. Карабина, Dina Sakaeva, Oleg Lipatov   +2 more
openalex   +2 more sources

Perception of oncology practitioners towards off-label use of anticancer medicines in Singapore

, 2017
Masnoon Saiyed, Pei Shi Ong, Lita Chew
openalex   +2 more sources

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Off-label use of lung sealants: the need for evidence-based guidelines and adequate indications for use. [PDF]

J Thorac Dis
Hermans BP, Li WWL, van der Heide SM, Verhagen AFTM.   +3 more
europepmc   +1 more source